Candidates for Intensive Local Treatment in cIIIA-N2 Non-Small Cell Lung Cancer: Deciphering the Heterogeneity.

[1]  W. Curran,et al.  Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. , 2015, The Lancet. Oncology.

[2]  R. Shaw,et al.  SERPINE1 and SMA expression at the invasive front predict extracapsular spread and survival in oral squamous cell carcinoma , 2014, British Journal of Cancer.

[3]  K. Nagayama,et al.  Prognostic impact of the current Japanese nodal classification on outcomes in resected non-small cell lung cancer. , 2014, Chest.

[4]  Kenji Suzuki,et al.  Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved. , 2014, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[5]  G. Michaud,et al.  Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[6]  L. Tanoue,et al.  Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[7]  A. Chang,et al.  Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.

[8]  K. Mori,et al.  Multicenter phase II study of concurrent high-dose (72Gy) three-dimensional conformal radiotherapy (3D-CRT) without elective nodal irradiation with chemotherapy using cisplatin and vinorelbine for unresectable stage III non-small cell lung cancer (NSCLC). , 2012 .

[9]  E. Miyaoka,et al.  Surgical Outcome of Stage IIIA- cN2/pN2 Non–Small-Cell Lung Cancer Patients in Japanese Lung Cancer Registry Study in 2004 , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[10]  M. Kris,et al.  Contemporary Results of Surgical Resection of Non-small Cell Lung Cancer After Induction Therapy: A Review of 549 Consecutive Cases , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[11]  H. Sato,et al.  Epidermal growth factor receptor gene copy number aberration at the primary tumour is significantly associated with extracapsular spread in oral cancer , 2011, British Journal of Cancer.

[12]  Masaaki Kawahara,et al.  Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Keitaro Matsuo,et al.  Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Okada,et al.  [New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)]. , 2009, Gan to kagaku ryoho. Cancer & chemotherapy.

[15]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[16]  L. Tanoue,et al.  The new lung cancer staging system. , 2009, Chest.

[17]  V. Rusch,et al.  The IASLC Lung Cancer Staging Project: A Proposal for a New International Lymph Node Map in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[18]  G. Giaccone,et al.  Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. , 2007, Journal of the National Cancer Institute.

[19]  Takehiko Fujisawa,et al.  Comparison of endobronchial ultrasound, positron emission tomography, and CT for lymph node staging of lung cancer. , 2006, Chest.

[20]  S. Thibodeau,et al.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. , 2005, Chest.

[21]  M. Tsuboi,et al.  Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station. , 2001, The Journal of thoracic and cardiovascular surgery.

[22]  R. Tsuchiya,et al.  Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. , 2001, Lung cancer.

[23]  J. Shah,et al.  Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland. , 1993, Surgery.

[24]  S. Singletary,et al.  Surgical management of groin nodal metastases from primary melanoma of the lower extremity. , 1992, Surgery, gynecology & obstetrics.

[25]  T. Naruke,et al.  Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer , 1982 .

[26]  B. Sorensen,et al.  Prognostic role of breach of lymph node capsule in nodal metastates from gastric carcinoma. , 1963, Acta chirurgica Scandinavica.

[27]  T. Kohno,et al.  Epidermal growth factor receptor mutation is associated with longer local control after definitive chemoradiotherapy in patients with stage III nonsquamous non-small-cell lung cancer. , 2015, International journal of radiation oncology, biology, physics.

[28]  G. Guyatt,et al.  Physicians Evidence-Based Clinical Practice Development : American College of Chest Thrombolytic Therapy Guideline Methodology for Antithrombotic and , 2008 .

[29]  W. Scott,et al.  Treatment of stage II non-small cell lung cancer. , 2003, Chest.

[30]  K. A. Hultborn,et al.  Mammary carcionma. The biologic character of mammary carcionma studied in 517 cases by a new form of malignancy grading. , 1960, Acta radiologica. Supplementum.